Role of heparinase in the gastrointestinal dysfunction of sepsis (Review)
- Authors:
- Ting-Ting Chen
- Jia-Jun Lv
- Ling Chen
- Yu-Wei Gao
- Li-Ping Liu
-
Affiliations: The First Clinical Medical School of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of Emergency Critical Care Medicine, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China - Published online on: December 6, 2021 https://doi.org/10.3892/etm.2021.11042
- Article Number: 119
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Tripathi CK, Banga J and Mishra V: Microbial heparin/Heparan Sulphate lyases: Potential and applications. Appl Microbiol Biotechno. 94:307–321. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ma Q, Dudas B, Hejna M, Cornelli U, Lee JM, Lorens S, Mervis R, Hanin I and Fareed J: The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. Thromb Res. 105:447–453. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Xavier RJ and Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature. 448:427–434. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Belmiro CL, Souza HS, Elia CC, Castelo-Branco MT, Silva FR, Machado RL and Pavão MS: Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease. Int J Colorectal Dis. 20:295–304. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF and Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:662–664. 1987.PubMed/NCBI View Article : Google Scholar | |
|
Chen S, He Y, Hu Z, Lu S, Yin X, Ma X, Lv C and Jin G: Heparanase mediates intestinal inflammation and injury in a mouse model of sepsis. J Histochem Cytochem. 65:241–249. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Fu L, Zhang F, Li G, Onishi A, Bhaskar U, Sun P and Linhardt RJ: Structure and activity of a new low-molecular-weight heparin produced by enzymatic ultrafiltration. J Pharm Sci. 103:1375–1383. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Weiss RJ, Esko JD and Tor Y: Targeting heparin and heparan sulfate protein interactions. Org Biomol Chem. 15:5656–5668. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kandrotas RJ: Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 22:359–374. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Castelli R, Porro F and Tarsia P: The heparins and cancer: Review of clinical trials and biological properties. Vasc Med. 9:205–213. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Casu B, Guerrini M and Torri G: Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Curr Pharm Des. 10:939–949. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Pike RN, Buckle AM, le Bonniec BF and Church FC: Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans. FEBS J. 272:4842–4851. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Walenga JM and Lyman GH: Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancer. Crit Rev Oncol Hematol. 88:1–18. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Li X, Liu Z, Luo M, Xi Y, Li C, Wang S and Yang R: Therapeutic effect of low-molecular-weight heparin on adult sepsis: A meta-analysis. Ann Palliat Med.Mar. 10:3115–3127. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, et al: Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med. 5:793–802. 1999.PubMed/NCBI View Article : Google Scholar | |
|
McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, Hircock M, Patel S, Barry E, Stubberfield C, et al: Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun. 276:1170–1177. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Yingying X, Yong Z, Zhenning W, Xue Z, Li J, Yang L and Huimian X: Role of heparanase-1 in gastric carcinoma invasion. Asian Pac J Cancer Prev. 10:151–154. 2009.PubMed/NCBI | |
|
Meirovitz A, Hermano E, Lerner I, Zcharia E, Pisano C, Peretz T and Elkin M: Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res. 71:2772–2780. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Shafat I, Pode D, Peretz T, Ilan N, Vlodavsky I and Nisman B: Clinical significance of urine heparanase in bladder cancer progression. Neoplasia. 10:125–130. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Boyango I, Barash U, Naroditsky I, Li JP, Hammond E, Ilan N and Vlodavsky I: Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res. 74:4504–4514. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R, Doviner V, Rubinstein AM, Ishai-Michaeli R, Atzmon R, Sherman Y, et al: Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest. 121:1709–1721. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Akbarshahi H, Axelsson JB, Said K, Malmström A, Fischer H and Andersson R: TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. J Transl Med. 9(219)2011.PubMed/NCBI View Article : Google Scholar | |
|
Fernandes CL, Escouto GB and Verli H: Structural glycobiology of heparinase II from Pedobacter heparinus. J Biomol Struct Dyn. 32:1092–1102. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Häcker U, Nybakken K and Perrimon N: Heparan sulphate proteoglycans: The sweet side of development. Nat Rev Mol Cell Biol. 6:530–541. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Fux L, Ilan N, Sanderson RD and Vlodavsky I: Heparanase: Busy at the cell surface. Trends Biochem Sci. 34:511–519. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Rivara S, Milazzo FM and Giannini G: Heparanase: A rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med Chem. 8:647–680. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Levy-Adam F, Feld S, Suss-Toby E, Vlodavsky I and Ilan N: Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans. PLoS One. 3(e2319)2008.PubMed/NCBI View Article : Google Scholar | |
|
Bass MD, Roach KA, Morgan MR, Mostafavi-Pour Z, Schoen T, Muramatsu T, Mayer U, Ballestrem C, Spatz JP and Humphries MJ: Syndecan-4-dependent Rac1 regulation determines directional migration in response to the extracellular matrix. J Cell Biol. 177:527–538. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Dovas A, Yoneda A and Couchman JR: PKCbeta-dependent activation of RhoA by syndecan-4 during focal adhesion formation. J Cell Sci. 119:2837–2846. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Tkachenko E, Elfenbein A, Tirziu D and Simons M: Syndecan-4 clustering induces cell migration in a PDZ-dependent manner. Circ Res. 98:1398–1404. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Zhang X, Han X, Xia K, Xu Y, Yang Y, Oshima K, Haeger SM, Perez MJ, McMurtry SA, Hippensteel JA, et al: Circulating heparin oligosaccharides rapidly target the hippocampus in sepsis, potentially impacting cognitive functions. Proc Natl Acad Sci USA. 116:9208–9213. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Ruan J, Trotter TN, Nan L, Luo R, Javed A, Sanderson RD, Suva LJ and Yang Y: Heparanase inhibits osteoblastogenesis and shifts bone marrow progenitor cell fate in myeloma bone disease. Bone. 57:10–17. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Smith PN, Freeman C, Yu D, Chen M, Gatenby PA, Parish CR and Li RW: Heparanase in primary human osteoblasts. J Orthop Res. 28:1315–1322. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Thompson CA, Purushothaman A, Ramani VC, Vlodavsky I and Sanderson RD: Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes. J Biol Chem. 288:10093–10099. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Shteingauz A, Boyango I, Naroditsky I, Hammond E, Gruber M, Doweck I, Ilan N and Vlodavsky I: Heparanase enhances tumor growth and chemoresistance by promoting autophagy. Cancer Res. 75:3946–3957. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Dunlop EA and Tee AR: mTOR and autophagy: A dynamic relationship governed by nutrients and energy. Semin Cell Dev Biol. 36:121–129. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Qiu P, Liu Y and Zhang J: Review: The role and mechanisms of macrophage autophagy in sepsis. Inflammation. 42:6–19. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR and Fuks Z: Expression of heparanase by platelets and circulating cells of the immune system: Possible involvement in diapedesis and extravasation. Invasion Metastasis. 12:112–127. 1992.PubMed/NCBI | |
|
Young E: The anti-inflammatory effects of heparin and related compounds. Thromb Res. 122:743–752. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Ilan N, Elkin M and Vlodavsky I: Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 38:2018–2039. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Li JP and Vlodavsky I: Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost. 102:823–828. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Flynn S and Eisenstein S: Inflammatory bowel disease presentation and diagnosis. Surg Clin North Am. 99:1051–1062. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Dias AM, Correia A, Pereira MS, Almeida CR, Alves I, Pinto V, Catarino TA, Mendes N, Leander M, Oliva-Teles MT, et al: Metabolic control of T cell immune response through glycans in inflammatory bowel disease. Proc Natl Acad Sci USA. 115:E4651–E4660. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Clayburgh DR, Shen L and Turner JR: A porous defense: The leaky epithelial barrier in intestinal disease. Lab Invest. 84:282–291. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Bode L, Salvestrini C, Park PW, Li JP, Esko JD, Yamaguchi Y, Murch S and Freeze HH: Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest. 118:229–238. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, Tilg H, Watson A and Wells JM: Intestinal permeability-a new target for disease prevention and therapy. BMC Gastroenterol. 14(189)2014.PubMed/NCBI View Article : Google Scholar | |
|
Baud V and Karin M: Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11:372–377. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Pender SL, Braegger C, Gunther U, Monteleone G, Meuli M, Schuppan D and Macdonald TT: Matrix metalloproteinases in necrotising enterocolitis. Pediatr Res. 54:160–164. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Hermano E, Lerner I and Elkin M: Heparanase enzyme in chronic inflammatory bowel disease and colon cancer. Cell Mol Life Sci. 69:2501–2513. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Chiba T, Marusawa H and Ushijima T: Inflammation-associated cancer development in digestive organs: Mechanisms and roles for genetic and epigenetic modulation. Gastroenterology. 143:550–563. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C and Ullman T: Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: A cohort study. Gastroenterology. 133:1099–1105. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Vlodavsky I, Ilan N, Nadir Y, Brenner B, Katz BZ, Naggi A, Torri G, Casu B and Sasisekharan R: Heparanase, heparin and the coagulation system in cancer progression. Thromb Res. 120 (Suppl 2):S112–S120. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Zheng L, Jiang G, Mei H, Pu J, Dong J, Hou X and Tong Q: Small RNA interference-mediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells. BMC Cancer. 10(33)2010.PubMed/NCBI View Article : Google Scholar | |
|
Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL and Ramsay G: SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Crit Care Med. 31:1250–1256. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD and Singer M: Sepsis Definitions Task Force. Developing a new definition and assessing new clinical criteria for septic shock: For the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 315:775–787. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Vincent JL, Jones G, David S, Olariu E and Cadwell KK: Frequency and mortality of septic shock in Europe and North America: A systematic review and meta-analysis. Crit Care. 23(196)2019.PubMed/NCBI View Article : Google Scholar | |
|
Bermejo-Martin JF, Martín-Fernandez M, López-Mestanza C, Duque P and Almansa R: Shared features of endothelial dysfunction between sepsis and its preceding risk factors (Aging and Chronic Disease). J Clin Med. 7(400)2018.PubMed/NCBI View Article : Google Scholar | |
|
Martin-Fernandez M, Vaquero-Roncero LM, Almansa R, Gómez-Sánchez E, Martín S, Tamayo E, Esteban-Velasco MC, Ruiz-Granado P, Aragón M, Calvo D, et al: Endothelial dysfunction is an early indicator of sepsis and neutrophil degranulation of septic shock in surgical patients. BJS Open. 4:524–534. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Floer M, Götte M, Wild MK, Heidemann J, Gassar ES, Domschke W, Kiesel L, Luegering A and Kucharzik T: Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am J Pathol. 176:146–157. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Yan Y, Ji Y, Su N, Mei X, Wang Y, Du S, Zhu W, Zhang C, Lu Y and Xing XH: Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review. Carbohydr Polym. 160:71–81. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sallisalmi M, Tenhunen J, Yang R, Oksala N and Pettilä V: Vascular adhesion protein-1 and syndecan-1 in septic shock. Acta Anaesthesiol Scand. 56:316–322. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Nelson A, Berkestedt I, Schmidtchen A, Ljunggren L and Bodelsson M: Increased levels of glycosaminoglycans during septic shock: Relation to mortality and the antibacterial actions of plasma. Shock. 30:623–627. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Weinbaum S, Tarbell JM and Damiano ER: The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng. 9:121–167. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Yini S, Heng Z, Xin A and Xiaochun M: Effect of unfractionated heparin on endothelial glycocalyx in a septic shock model. Acta Anaesthesiol Scand. 59:160–169. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX, et al: The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med. 18:1217–1223. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Obritsch MD, Fish DN, MacLaren R and Jung R: Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: Epidemiology and treatment options. Pharmacotherapy. 25:1353–1364. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Dzvova N, Colmer-Hamood JA, Griswold JA and Hamood AN: Heparinase is essential for Pseudomonas aeruginosa virulence during thermal injury and infection. Infect Immun. 86:e00755–e00817. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Dzvova N, Colmer-Hamood JA, Griswold JA and Hamood AN: Isolation and characterization of HepP: A virulence-related Pseudomonas aeruginosa heparinase. BMC Microbiol. 17(233)2017.PubMed/NCBI View Article : Google Scholar | |
|
Martin L, De Santis R, Koczera P, Simons N, Haase H, Heinbockel L, Brandenburg K, Marx G and Schuerholz T: The synthetic antimicrobial peptide 19-2.5 interacts with heparanase and heparan sulfate in murine and human sepsis. PLoS One. 10(e0143583)2015.PubMed/NCBI View Article : Google Scholar | |
|
Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS, Rimmer E, Houston BL, McIntyre L, Fox-Robichaud AE, et al: The efficacy and safety of heparin in patients with sepsis: A systematic review and metaanalysis. Crit Care Med. 43:511–518. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Cho SX, Berger PJ, Nold-Petry CA and Nold MF: The immunological landscape in necrotising enterocolitis. Expert Rev Mol Med. 18(e12)2016.PubMed/NCBI View Article : Google Scholar | |
|
Reintam Blaser A, Malbrain ML, Starkopf J, Fruhwald S, Jakob SM, De Waele J, Braun JP, Poeze M and Spies C: Gastrointestinal function in intensive care patients: Terminology, definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems. Intensive Care Med. 38:384–394. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Chen H, Zhang H, Li W, Wu S and Wang W: Acute gastrointestinal injury in the intensive care unit: A retrospective study. Ther Clin Risk Manag. 11:1523–1529. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Hu B, Sun R, Wu A, Ni Y, Liu J, Guo F, Ying L, Ge G, Ding A, Shi Y, et al: Severity of acute gastrointestinal injury grade is a predictor of all-cause mortality in critically ill patients: A multicenter, prospective, observational study. Crit Care. 21(188)2017.PubMed/NCBI View Article : Google Scholar | |
|
Reintam A, Parm P, Kitus R, Starkopf J and Kern H: Gastrointestinal failure score in critically ill patients: A prospective observational study. Crit Care. 12(R90)2008.PubMed/NCBI View Article : Google Scholar | |
|
Fleischmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, Angus DC and Reinhart K: International Forum of Acute Care Trialists. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 193:259–272. 2016.PubMed/NCBI View Article : Google Scholar |
